Table 1.
Demographics and clinical characteristics of the two cohorts analyzed in the study.
| Covariate | TCIA/TCGA-GBM cohort (n = 254) | VUMC Cohort (n = 170) | P value* |
|---|---|---|---|
| Age, median [IQR] | 59.5 [52, 69] | 61.0 [51.8, 68.6] | 0.79* |
| Age ≤ 50, n (%) | 56 (22.0%) | 35 (20.6%) | 0.81 |
| KPS, median [IQR] | 80 [60–80] | 80 [70–90] | 0.86* |
| 100–80 | 160/214 (74.8%) | 112 (65.9%) | 0.07 |
| 70–50 | 44/214 (20.6%) | 51 (30.0%) | 0.04 |
| Under 50 | 10/214 (4.7%) | 7 (4.1%) | 1 |
| Unknown | 40/254 (15.7%) | — | — |
| Temozolomide, n (%) | 168 (66.1%) | 146 (85.9%) | <0.0001 |
| Radiation Therapy, n (%) | 191 (75.2%) | 154 (90.6%) | <0.0001 |
| IDH Mutants, n/total (%) | 12/203 (5.9%) | 10 (5.9%) | 1 |
| IDH Status Missing, n/total (%) | 51/254 (20.1%) | — | — |
| G-CIMP Status, n/total (%) | 14/249 (5.6%) | — | — |
| MGMT Promoter Methylation, n/total (%) | 84/166 (50.6%) | 60 (35.3%) | 0.006 |
| MGMT Promoter Methylation Status Missing, n/total (%) | 88/254 (35.6%) | — | — |
| Extent of Resection | |||
| Gross total | — | 28 (16.5%) | — |
| Near total | — | 34 (20.0%) | — |
| Subtotal | — | 108 (63.5%) | — |
| Tumor Volume (cm3), median [IQR] | 33.0 [16.1–60.4] | 36.2 [16.9–58.6] | 0.66* |
| VSVZ Contact, n (%) | 124 (48.8%) | 95 (55.9%) | 0.17 |
Abbreviations: IQR – interquartile range, KPS – Karnofsky Performance Scale score, VSVZ – ventricular-subventricular zone; P values marked with an * asterisk are obtained from Mann-Whitney U tests, all others are obtained from Fisher’s Exact tests.